Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TRO40303 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| TRO40303 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TRO40303 | DRUG | 6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min) |
| Placebo | DRUG | single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV) |
Inclusion Criteria: 1. Male and Female with non childbearing potential patients 2. Age \> 18 years old 3. First acute myocardial infarction 4. Occlusion should affect the following coronary arteries: LAD,or the dominant or balanced RCA, or the dominant or balanced LCx 5. Acute myocardial infarction...
TRO40303 is an investigational small molecule being studied for the treatment of acute myocardial infarction, commonly known as a heart attack. It is designed to reduce reperfusion injury in patients undergoing percutaneous coronary intervention for acute myocardial infarction. The drug is in Phase 2 clinical development.
TRO40303 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The drug is currently in Phase 2 clinical development for the treatment of acute myocardial infarction.
TRO40303 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved by regulatory authorities for commercial use.
TRO40303 has been studied in one clinical trial, identified as NCT01374321. This Phase 2 study evaluated the safety and efficacy of TRO40303 for reduction of reperfusion injury in patients undergoing percutaneous coronary intervention for acute myocardial infarction. The trial was completed and enrolled 168 participants.
TRO40303 is a small molecule designed to reduce reperfusion injury in patients with acute myocardial infarction. Reperfusion injury occurs when blood flow is restored to ischemic heart tissue, potentially causing additional damage. The drug aims to mitigate this damage during percutaneous coronary intervention procedures.